© 1991 British Society for Rheumatology
other |
MONOCLONAL ANTIBODY TREATMENT IN RHEUMATOID ARTHRITIS: THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF A CD7 MONOCLONAL ANTIBODY

Rheumatology Unit, United Medical and Dental Schools, Guy's Hospital London, England
*Department of Histopathology, Lewisham Hospital, and the Royal Free Hospital School of Medicine London, England
Department of Immunology, The Royal Free Hospital School of Medicine London, England
Correspondence to:
Correspondence to Professor G. Panayi, Rheumatology Unit, United Medical and Dental Schools, Guy's Hospital, London SE1 9RT
Six patients with rheumatoid arthritis were treated with a CD7 mouse monoclonal antibody, RFT2, daily for 14 days. Only two patients had a significant improvement in clinical disease activity which lasted 714 days. No serious adverse effects occurred although all patients developed antibodies against mouse immunoglobulin. During treatment T-lymphocyte numbers decreased and T-lymphocyte CD7 expression was absent in all but one patient.
KEY WORDS: Immunotherapy, Antigen modulation, RA